Your browser is no longer supported. Please, upgrade your browser.
AMRX Amneal Pharmaceuticals, Inc. monthly Stock Chart
Amneal Pharmaceuticals, Inc.
Index- P/E9.66 EPS (ttm)0.41 Insider Own0.10% Shs Outstand147.56M Perf Week-3.89%
Market Cap1.16B Forward P/E5.71 EPS next Y0.69 Insider Trans0.00% Shs Float116.04M Perf Month-9.40%
Income62.00M PEG- EPS next Q0.13 Inst Own69.80% Short Float5.70% Perf Quarter-3.89%
Sales1.88B P/S0.62 EPS this Y77.10% Inst Trans-0.08% Short Ratio5.65 Perf Half Y-15.96%
Book/sh2.04 P/B1.94 EPS next Y11.79% ROA1.50% Target Price4.44 Perf Year5.05%
Cash/sh0.96 P/C4.12 EPS next 5Y-12.10% ROE21.40% 52W Range2.40 - 5.79 Perf YTD-18.05%
Dividend- P/FCF5.42 EPS past 5Y-40.00% ROI-14.70% 52W High-31.78% Beta1.23
Dividend %- Quick Ratio1.60 Sales past 5Y22.20% Gross Margin33.00% 52W Low64.58% ATR0.24
Employees5500 Current Ratio2.30 Sales Q/Q37.30% Oper. Margin2.60% RSI (14)41.40 Volatility3.83% 6.04%
OptionableYes Debt/Eq9.59 EPS Q/Q97.00% Profit Margin3.30% Rel Volume0.95 Prev Close4.07
ShortableYes LT Debt/Eq9.49 EarningsNov 06 BMO Payout0.00% Avg Volume1.17M Price3.95
Recom3.00 SMA20-6.86% SMA50-10.42% SMA200-5.37% Volume1,111,402 Change-2.95%
Jul-27-20Initiated Goldman Sell $4
May-12-20Upgrade Guggenheim Sell → Neutral
Dec-12-19Downgrade Raymond James Outperform → Mkt Perform
Nov-12-19Downgrade JP Morgan Neutral → Underweight
Nov-07-19Downgrade SVB Leerink Outperform → Mkt Perform
Jul-22-19Upgrade SVB Leerink Mkt Perform → Outperform $11 → $5
Jul-11-19Downgrade RBC Capital Mkts Outperform → Sector Perform $11 → $6
Jul-08-19Upgrade Piper Jaffray Neutral → Overweight
Jun-11-19Initiated Barclays Equal Weight $9
May-21-19Upgrade Raymond James Mkt Perform → Strong Buy $13
Mar-20-19Initiated SunTrust Buy $16
Mar-08-19Downgrade SVB Leerink Outperform → Mkt Perform $16 → $12
Dec-14-18Downgrade Morgan Stanley Overweight → Equal-Weight
Oct-16-18Downgrade SunTrust Buy → Hold
Aug-13-18Upgrade RBC Capital Mkts Sector Perform → Outperform
Jul-23-18Initiated Morgan Stanley Overweight $22
Jun-22-18Initiated B. Riley FBR, Inc. Buy $26
Nov-23-20 10:24AM  
Nov-16-20 09:45AM  
Nov-11-20 08:35AM  
Nov-10-20 05:09AM  
Nov-06-20 09:30PM  
Nov-05-20 10:08AM  
Oct-30-20 12:30PM  
Oct-29-20 05:50PM  
Oct-22-20 12:10PM  
Oct-21-20 10:46AM  
Oct-20-20 11:30AM  
Oct-15-20 10:26AM  
Oct-14-20 06:15AM  
Oct-08-20 03:10PM  
Sep-01-20 08:00AM  
Aug-25-20 09:00AM  
Aug-06-20 08:35AM  
Aug-03-20 12:08PM  
Jul-31-20 05:45PM  
Jul-30-20 12:33PM  
Jul-23-20 05:45PM  
Jul-22-20 12:10PM  
Jul-17-20 05:45PM  
Jul-16-20 07:29AM  
Jul-13-20 09:44AM  
Jul-10-20 08:00AM  
Jul-09-20 07:18AM  
Jul-08-20 05:50PM  
Jul-07-20 11:40AM  
Jun-30-20 10:21AM  
Jun-26-20 10:48AM  
Jun-19-20 11:40AM  
Jun-16-20 08:33AM  
Jun-14-20 09:33PM  
Jun-12-20 08:49AM  
Jun-09-20 08:47AM  
Jun-08-20 07:22AM  
Jun-03-20 11:40AM  
May-26-20 07:49AM  
May-18-20 11:40AM  
May-17-20 10:27AM  
May-15-20 12:00PM  
May-12-20 10:09AM  
May-11-20 08:00PM  
May-08-20 08:53AM  
May-06-20 06:49PM  
Apr-24-20 04:05PM  
Apr-16-20 07:00AM  
Apr-15-20 04:30PM  
Apr-10-20 11:18AM  
Apr-07-20 09:46AM  
Mar-26-20 04:30PM  
Mar-25-20 08:16AM  
Mar-24-20 09:57AM  
Mar-20-20 04:15PM  
Mar-11-20 05:36PM  
Feb-26-20 07:55AM  
Feb-19-20 12:31PM  
Jan-27-20 11:40AM  
Jan-24-20 06:59AM  
Jan-22-20 09:24AM  
Jan-21-20 08:41AM  
Jan-16-20 09:35AM  
Jan-10-20 11:40AM  
Dec-31-19 05:07AM  
Dec-26-19 04:15PM  
Dec-17-19 07:19PM  
Dec-16-19 06:59AM  
Dec-13-19 09:23AM  
Dec-12-19 12:08PM  
Dec-10-19 06:59AM  
Dec-03-19 08:00AM  
Dec-02-19 04:05PM  
Nov-27-19 12:36PM  
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates in two segments, Generics and Specialty. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, manufacture, and sale of branded pharmaceutical products primarily for central nervous system disorders, endocrinology, parasitic infections, and other therapeutic areas. It also offers licensed and owned, niche, and mature branded products, as well as Rytary for the treatment of Parkinsons Disease; Zomig for the treatment of migraine headaches; Emverm a chewable tablets for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; and Unithroid for the treatment of hypothyroidism. The company sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. It has operations in the United States, India, Ireland, and internationally. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is based in Bridgewater, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kiely JohnDirectorMay 19Buy4.4010,00044,00010,000May 19 11:46 AM
George Jeffrey P.DirectorMay 15Buy4.1623,81099,05023,810May 15 04:15 PM
MEISTER PAUL MDirectorMar 18Buy2.71204,210553,409353,649Mar 19 05:48 PM
MEISTER PAUL MDirectorMar 17Buy2.79149,439416,935149,439Mar 19 05:48 PM
Patel ChintuCo-CEO and DirectorMar 10Buy3.09100,000309,000356,107Mar 11 07:54 PM
Patel Chirag K.President, Co-CEO & DirectorMar 10Buy3.09100,000309,000356,107Mar 11 07:54 PM
Patel Chirag K.President, Co-CEO & DirectorMar 04Buy3.9758,938233,984256,107Mar 10 09:15 PM
Patel ChintuCo-CEO and DirectorMar 04Buy3.9758,765233,297256,107Mar 10 09:13 PM
Patel ChintuCo-CEO and DirectorMar 03Buy3.88156,539607,371197,342Mar 10 09:13 PM
Patel GautamDirectorMar 03Buy3.94117,889464,483156,107Mar 10 09:14 PM
Patel Chirag K.President, Co-CEO & DirectorMar 03Buy3.88156,421606,913197,169Mar 10 09:15 PM
Patel Chirag K.President, Co-CEO & DirectorMar 02Buy3.8734,641134,06140,748Mar 10 09:15 PM
Patel GautamDirectorMar 02Buy3.8832,111124,59138,218Mar 10 09:14 PM
Patel ChintuCo-CEO and DirectorMar 02Buy3.8734,696134,27440,803Mar 10 09:13 PM
Todisco JosephSVP, Specialty CommercialFeb 28Buy3.6240,000144,800246,845Mar 03 07:26 PM